Researchers at UT Southwestern Medical Center have developed a novel artificial intelligence model to improve the detection of breast cancer metastasis, which could reduce the need for needle or surgical biopsies.
The healthcare sector’s necessary transition towards electronic health records (EHRs) has transformed patient care and operational efficiency.
Leal Health announced a first-of-its-kind GenAI single point of access technology designed to allow healthcare providers, caregivers, and cancer patients to understand diagnostics and identify personalized treatment options to support the treatment decision process.
Tumor heterogeneity is a well-recognized hurdle to successful cancer therapy, often leading to resistance and treatment failure.
ArteraAI has validated its first multimodal artificial intelligence digital pathology-based post-radical prostatectomy biomarker for stratifying risk of metastasis and identifying differential absolute benefit for the addition of hormone therapy to salvage radiation therapy in radical prostatectomy patients with biochemical recurrence.
Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care, unveiled the results of a new UCLA study examining the role of AI in identifying tumor margins and predicting the efficacy of focal therapy treatments.
Can AI-enabled technology safeguard hospitals, pharmacies, and medical devices from cyberattacks?
Topline results from a pooled clinical study show that Mainz Biomed’s portfolio of proprietary novel gene expression (mRNA) biomarkers can be used in a next generation version of the company’s colorectal cancer screening tool. The study included new patients and subjects from Mainz Biomed’s ColoFuture (Europe) and eAArly DETECT (U.S.) clinical trials. The topline results confirm the positive efficacy results previously reported with a sensitivity for colorectal cancer of 92% with a specificity of 90% and a sensitivity for advanced adenoma of 82%, the company said.
Andrew Smith was named chair of St. Jude’s Diagnostic Imaging Department. He succeeds Beth McCarville, who was interim chair of the department since the death of Zoltan Patay, who held the position from 2017 to 2022.
COTA, a leader in real-world data and analytics for oncology, is entering a collaboration with Sanofi to use RWD and artificial intelligence to increase the speed of oncology trials, including for multiple myeloma.
